Every letter we have printed

Where the substudy population volunteered for an additional scan, they are a self-selected subset of an already selected trial population. Two layers of selection, and every figure downstream inherits both.

Applying trial findings to material of unknown provenance adds an uncertainty that no statistical caveat in the paper covers. Your publication is unusual in making that point where it belongs, which is beside every extrapolation rather than in a standing disclaimer.

The resistance training literature has decades of work on preserving lean mass during energy deficit, and this field barely cites it. The two bodies of work would inform each other considerably.

The commonest reason for an intermittent pattern is supply or cost rather than design, which means much of what looks like a strategy is an accommodation. Reporting it as a strategy misdescribes what is happening.

Whatever pattern somebody follows, recording it makes the difference between an experience and a record. The absence of documented individual patterns is the reason nothing can be learned from a very large amount of use.

Reported adherence in the maintenance phase of published trials is high and self-reported adherence outside them is not measured at all. Any comparison between trial outcomes and general experience has that gap in it and rarely acknowledges it.

Nothing in the published evidence supports or refutes indefinite continuation, because nobody has run a study of that length. Where the honest answer is that the question is open, saying so is not a failure of reporting.

Tamper-evident packaging costs a few pence and would answer most of the questions custody is meant to answer. A sealed bag with a serial number that the laboratory records on receipt is not a chain of custody and it is a great deal better than nothing.

Customs inspection is a break in custody that nobody records and everybody experiences. A parcel opened, examined and resealed by an authority is entirely lawful and entirely undocumented from the laboratory’s point of view.

Blinding at the laboratory end is the easy half and the half everybody talks about. An analyst who does not know which supplier they are testing is protected against one bias and against none of the others in the chain.

What I would most like to see is a badge that says how many determinations have been commissioned in total, not how many passed. A ratio is a fact about a supplier; a single pass is a fact about a sample.

A long half-life means every stop is a taper in pharmacokinetic terms, whether or not the dose is stepped down. The concentration declines over weeks regardless, which is a point worth making before any discussion of tapering schedules.

Tapering is borrowed language from drug classes with withdrawal syndromes, and there is no equivalent phenomenon here. Whether a gradual reduction changes the trajectory is an open question rather than an established practice, and the borrowed word implies an answer.

Confounding by indication is severe in observational work on this class, since the population using these compounds differs systematically from the population not using them. Adjustment helps and does not eliminate it, and the residual should be stated.

Severe persistent abdominal pain is not a tolerability question and should never be filed as one. Your article says so clearly. I would place it earlier in the piece, because a reader who is unwell may not reach the fifth section.

The run-in and titration phases are where most of the reported events occur and where the fewest measurements are taken. It is an understandable design choice and it means the noisiest period is also the least documented.

I stopped at week six because I could not keep anything down for three days, and my prescriber told me I had not given it a fair chance. Reading your definition of dose-limiting, I think what happened was that nobody offered me the option of going back to the lower dose. It was escalate or stop.

An effect is dose-limiting when it stops the escalation, and that is a decision rather than a symptom threshold. Your framing makes that visible, which matters because the same symptom is tolerable in one person’s circumstances and not in another’s.

Sealed does not mean unopened. A crimp seal can be lifted and replaced by anybody with the right tool, and the visual check most buyers perform would not detect it. Tamper-evident and sealed are different properties sold under one word.

The weakest link is almost always the domestic leg. A vial delivered to a residential address, kept in a kitchen for a week and then posted onward has lost any custody claim it had, and this is the ordinary case rather than an unusual one.

Quantity tested against quantity released deserves a line. A determination on a hundred milligrams drawn from a five-kilogram campaign is a different kind of evidence from a determination on a vial drawn from a hundred-vial fill, and the certificate reports both in the same font.

The batch number on the vial matching the batch number on the certificate is the single check I ask new staff to perform, and it takes four seconds. It is not sufficient and it is astonishingly informative, because the documents that fail it fail it obviously.

I supply research peptides and I want to push back on the specification column point. We sell from a catalogue of six hundred products. Writing a meaningful individual specification for each would take a year of somebody’s time, and a generic one would be exactly the decorative limit your article criticises. What would you actually have us do?

Working through your anatomy against the documents from three of the companies in your dossier programme, I found all of them carried method, threshold and a dated determination. My complaint is not with those; it is with everything I am sent by sellers who have never been near an independent laboratory.

The tone is the achievement. Serious without being solemn, and sceptical without the sneer that usually accompanies it in coverage of this subject.

Storage becomes a maintenance problem at scale. Somebody holding a year of supply has a stability question that somebody holding a month does not, and the practical literature is written almost entirely for the second case.

Supply interruption is the underdiscussed maintenance risk. A plan that depends on continuous availability of a specific product is a plan with an external dependency, and the last two years have shown how that dependency behaves under stress.

You describe the maintenance strategy of stepping down one dose and holding for eight to twelve weeks as something clinicians report doing, and then say it is not a recommendation. That distinction will be lost on most readers, and printing the protocol makes you a source for it whether you intend to be or not.

Cost is the leading reason people stop and it is discussed least, because it is not a clinical variable and therefore does not appear in clinical writing. Your treating it as a primary reason rather than a footnote is the right decision.

Three months after stopping, my HbA1c had barely moved and I concluded I had got away with it. Six months after stopping, it was back where it started. Your point about the lag is the single most useful sentence I have read on this subject.

Where the seller ships directly to the laboratory, custody is clean and the sample is chosen. Where the buyer ships, custody is broken and the sample is representative. The trade is not acknowledged anywhere in the literature I have read.

I would like to see the phrase used more carefully in this publication as well. Where the history is a courier number and a photograph, say so. Where it is a signed transfer record, say that. The reader can weigh either if they are told which they are reading.

You note that no service offers sterility testing and that it takes fourteen days. Worth saying more plainly: a purity certificate and a sterility assurance are not merely different tests, they are different disciplines with different facilities, and no amount of chromatography will ever bear on it.

What worries me more than shading is selective publication. A seller who commissions four determinations and publishes the best one has not corrupted any laboratory. Every document is genuine. The set is the misrepresentation, and no laboratory is in a position to detect it.

A quiet objection to the whole framing. Blind purchasing treats suppliers as adversaries, which is a reasonable design assumption and a poor description of most of the trade. The programmes that have learned most have been the ones willing to ask questions as well as run tests.

Comparing results across laboratories is where readers come unstuck, because the interval belongs to the method and the method differs between analysers. A value that reads high against one laboratory’s range can sit comfortably within another’s, and neither laboratory is wrong.

A reference interval is a description of where the central portion of a reference population fell, which means five per cent of a healthy population sits outside it by construction. It is not a definition of normal and it is read as one universally.

Frequency deserves a word. Repeating a panel monthly during a period of change produces a series in which most movement is variation rather than trend, and reading each report as news is a recipe for chasing noise.

Glycated haemoglobin reflects roughly the preceding two to three months, weighted towards the more recent weeks, which means a value taken four weeks after a change is a poor test of that change. It is the commonest misreading of the analyte and it is entirely avoidable by waiting.

Whoever decided that a piece should say what it does not allege deserves credit. That paragraph does more to keep the argument honest than any amount of hedging elsewhere.